A multicenter phase 2, double-blind, placebocontrolled, randomized, parallel-group study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of UCB0022 in study

This multicenter Phase 2, double-blind, placebo-controlled, randomized, parallel-group study evaluated UCB0022 in study participants with advanced Parkinson’s disease. The trial was designed to characterize the efficacy, safety, tolerability and pharmacokinetics of UCB0022 in a rigorously controlled, blinded setting. The study’s protocol emphasized randomized allocation and parallel-group comparisons against placebo to provide robust data on clinical outcomes and drug behavior in the target population.

The research focused on proof-of-concept questions central to advancing UCB0022 through clinical development: whether the investigational agent demonstrates measurable clinical benefit signals in participants with advanced Parkinson’s disease, whether its adverse-effect profile is acceptable relative to potential therapeutic gains and how the agent is absorbed, distributed, metabolized, and eliminated in this patient population.

The study’s multicenter design allowed enrollment and data collection across multiple clinical sites, strengthening the generalizability of findings and facilitating the recruitment of participants with advanced disease stages who meet protocol-defined inclusion criteria.

Outcomes from this trial would be expected to inform go/no-go decisions for subsequent Phase 3 development, refine dosing and monitoring recommendations, and contribute to the evidence base regarding UCB0022’s potential role in treating advanced Parkinson’s disease.